{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:21:29Z","timestamp":1783092089106,"version":"3.54.6"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00702-026-03121-3","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:20:50Z","timestamp":1777980050000},"page":"965-969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic botulinum toxin preparations: an update"],"prefix":"10.1007","volume":"133","author":[{"given":"Hans","family":"Bigalke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Frevert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"3121_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/asj\/sjw272","volume":"38","author":"B Ascher","year":"2018","unstructured":"Ascher B, Kestemont P, Boineau D, Bodokh I, Stein A, Heckmann M, Dendorfer M, Pavicic T, Volteau M, Tse A, Picaut P, Rzany B (2018) Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthet Surg J 38:183\u2013191. https:\/\/doi.org\/10.1093\/asj\/sjw272","journal-title":"Aesthet Surg J"},{"key":"3121_CR2","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/j.jaip.2021.03.002","volume":"9","author":"ML Caballero","year":"2021","unstructured":"Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA Jr (2021) Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. J Allergy Clin Immunol Pract 9:2968\u20132982","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3121_CR3","unstructured":"Clinical Trials (2025) https:\/\/clinicaltrials.eu\/inn\/clostridium-botulinum-neurotoxin-serotype-a-b\/."},{"key":"3121_CR4","first-page":"956","volume":"17","author":"A Dhawan","year":"2018","unstructured":"Dhawan A, Vitarella D (2018) The potential role of botulinum toxin in improving superficial cutaneous scarring: a review. J Drugs Dermatol 17:956\u2013958","journal-title":"J Drugs Dermatol"},{"key":"3121_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00702-010-0372-0","volume":"117","author":"D Dressler","year":"2010","unstructured":"Dressler D (2010) Comparing Botox\u00ae and Xeomin\u00ae for the treatment of axillar hyperhidrosis. J Neural Transm 117:317\u2013319","journal-title":"J Neural Transm"},{"key":"3121_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.mib.2012.05.012","volume":"15","author":"D Dressler","year":"2012","unstructured":"Dressler D (2012) Clinical applications of botulinum toxin. Curr Opin Microbiol 15:325\u2013336","journal-title":"Curr Opin Microbiol"},{"key":"3121_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000067023","volume":"49","author":"D Dressler","year":"2003","unstructured":"Dressler D, Benecke R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34\u201338","journal-title":"Eur Neurol"},{"key":"3121_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s00415-005-0774-3","volume":"252","author":"D Dressler","year":"2005","unstructured":"Dressler D, Bigalke H (2005) Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. J Neurol 252:904\u2013907","journal-title":"J Neurol"},{"key":"3121_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00415-003-1129-6","volume":"250","author":"D Dressler","year":"2003","unstructured":"Dressler D, Bigalke H, Benecke (2003) Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 250:967\u2013969","journal-title":"J Neurol"},{"key":"3121_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00702-011-0719-1","volume":"119","author":"D Dressler","year":"2012","unstructured":"Dressler D, Mander G, Fink K (2012) Measuring the potency labelling of onabotulinumtoxinA (Botox\u00ae) and Xeomin\u00ae in an LD50 assay. J Neural Transm 119:13\u201315","journal-title":"J Neural Transm"},{"key":"3121_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00702-013-1076-z","volume":"121","author":"D Dressler","year":"2014","unstructured":"Dressler D, Tacik P, Adib Saberi F (2014) Botulinum toxin therapy of cervical dystonia: comparing Botox\u00ae and Xeomin\u00ae. J Neural Transm 121:29\u201331","journal-title":"J Neural Transm"},{"key":"3121_CR12","first-page":"527","volume":"123","author":"D Dressler","year":"2016","unstructured":"Dressler D, Adib Saberi F, Bigalke H (2016) Botulinum toxin therapy: reduction of injection site pain by pH-normalisation. JNT 123:527\u2013531","journal-title":"JNT"},{"key":"3121_CR13","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00702-018-1897-x","volume":"125","author":"D Dressler","year":"2018","unstructured":"Dressler D, Pan L, Bigalke H (2018) Comparing IncobotulinumtoxinA (Xeomin\u00ae) and OnabotulinumtoxinA (Botox\u00ae): identical potency labelling in the hemidiaphragm assay. J Neural Transm 125:1351\u20131354","journal-title":"J Neural Transm"},{"key":"3121_CR14","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00702-019-02029-5","volume":"126","author":"D Dressler","year":"2019","unstructured":"Dressler D, Kollewe K, Kruger THC, Gade N, Sikorra S, Bigalke H (2019) Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use. J Neural Transm 126:1337\u20131340","journal-title":"J Neural Transm"},{"key":"3121_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/toxins13060370","volume":"13","author":"D Dressler","year":"2021","unstructured":"Dressler D, Pan L, Su J, Teng F, Jin L (2021) Lantox-the Chinese botulinum toxin drug-complete English bibliography and comprehensive formalised literature review. Toxins 13:370","journal-title":"Toxins"},{"key":"3121_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.toxicon.2010.12.019","volume":"57","author":"KH Eisele","year":"2011","unstructured":"Eisele KH, Fink K, Vey M, Taylor HV (2011) Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 57:555\u2013565","journal-title":"Toxicon"},{"key":"3121_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0304-3940(98)00775-7","volume":"256","author":"R Eleopra","year":"1998","unstructured":"Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256:135\u2013138","journal-title":"Neurosci Lett"},{"key":"3121_CR18","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.clinph.2012.11.004","volume":"124","author":"R Eleopra","year":"2013","unstructured":"Eleopra R, Montecucco C, Devigili G, Lettieri C, Rinaldo S, Verriello L, Pirazzini M, Caccin P, Rossetto O (2013) Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study. Clin Neurophysiol 124:999\u20131004","journal-title":"Clin Neurophysiol"},{"key":"3121_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/anae.14497","volume":"74","author":"S Farooque","year":"2019","unstructured":"Farooque S, Kenny M, Marshall SD (2019) Anaphylaxis to intravenous gelatin-based solutions: a case series examining clinical features and severity. Anaesthesia 74:174\u2013179","journal-title":"Anaesthesia"},{"key":"3121_CR20","unstructured":"FDA Access Data. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/103846s5120lbl.pdf"},{"key":"3121_CR21","unstructured":"Grandview Research (2025) Botulinum toxin market size and trends. last retrieved 26.05.25. www.grandviewresearch.com\/industry-analysis\/botulinum-toxin-market"},{"key":"3121_CR22","first-page":"719","volume":"87","author":"P Hambleton","year":"1994","unstructured":"Hambleton P, Pickett AM (1994) Potency equivalence of botulinum toxin preparations. J R Soc Med 87:719 (Erratum in: J R Soc Med 1995 88:60.)","journal-title":"J R Soc Med"},{"key":"3121_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mdc3.12613","volume":"5","author":"J Jankovic","year":"2018","unstructured":"Jankovic J, Truong D, Patel AT, Brashear A, Evatt M, Rubio RG, Oh CK, Snyder D, Shears G, Comella C (2018) Injectable DaxibotulinumtoxinA in cervical dystonia: a phase 2 dose-escalation multicenter study. Mov Disord Clin Pract 5:273\u2013282","journal-title":"Mov Disord Clin Pract"},{"key":"3121_CR24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/mds.20468","volume":"20","author":"A Marchetti","year":"2005","unstructured":"Marchetti A, Magar R, Findley L, Larsen JP, Pirtosek Z, Ruzicka E, Jech R, Slawek J, Ahmed F (2005) Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 20:937\u2013944","journal-title":"Mov Disord"},{"key":"3121_CR25","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3390\/toxins17120598","volume":"17","author":"MU Martin","year":"2025","unstructured":"Martin MU, Frevert J, Park JY, Cui H, Curry A, Loh WQ (2025) Immunological considerations of polysorbate as an excipient in botulinum neurotoxin type A formulations: a narrative review. Toxins (Basel) 17:598. https:\/\/doi.org\/10.3390\/toxins17120598","journal-title":"Toxins (Basel)"},{"key":"3121_CR26","unstructured":"news.abbvie (2023) https:\/\/news.abbvie.com\/2023-10-24-Allergan-Aesthetics-Announces-Positive-Topline-Results-from-Two-Pivotal-Phase-3-Studies-of-TrenibotulinumtoxinE-BoNT-E-for-the-Treatment-of-Glabellar-Lines. last checked 25.05.25"},{"key":"3121_CR27","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00702-019-02100-1","volume":"126","author":"L Pan","year":"2019","unstructured":"Pan L, Bigalke H, Kopp B, Jin L, Dressler D (2019) Comparing lanbotulinumtoxinA (Hengli\u00ae) with onabotulinumtoxinA (Botox\u00ae) and incobotulinumtoxinA (Xeomin\u00ae) in the mouse hemidiaphragm assay. J Neural Transm 126:1625\u20131629","journal-title":"J Neural Transm"},{"key":"3121_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1006\/taap.1994.1181","volume":"128","author":"LB Pearce","year":"1994","unstructured":"Pearce LB, Borodic GE, First ER, MacCallum RD (1994) Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 128:69\u201377","journal-title":"Toxicol Appl Pharmacol"},{"key":"3121_CR29","first-page":"3233","volume":"125","author":"L Peng","year":"2012","unstructured":"Peng L, Berntsson RP, Tepp WH, Pitkin RM, Johnson EA, Stenmark P, Dong M (2012) Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J Cell Sci 125:3233\u20133242","journal-title":"J Cell Sci"},{"key":"3121_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116516","volume":"407","author":"L Pons","year":"2019","unstructured":"Pons L, Vilain C, Volteau M, Picaut P (2019) Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport(R)). J Neurol Sci 407:116516. https:\/\/doi.org\/10.1016\/j.jns.2019.116516","journal-title":"J Neurol Sci"},{"key":"3121_CR31","first-page":"61","volume":"364","author":"A Rummel","year":"2013","unstructured":"Rummel A (2013) Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr Top Microbiol Immunol 364:61\u201390","journal-title":"Curr Top Microbiol Immunol"},{"key":"3121_CR32","unstructured":"Rummel A, Weil T, Gutscaits A (2005) Carrier for targeting nerve cells: patent: toxogen GmbH, Hannover filed: 26th April 2005 Application no.: DE102005019302.1; PCT\/EP2006\/003896"},{"key":"3121_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8030065","volume":"8","author":"F Scaglione","year":"2016","unstructured":"Scaglione F (2016) Conversion ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in clinical practice. Toxins 8:65. https:\/\/doi.org\/10.3390\/toxins8030065","journal-title":"Toxins"},{"key":"3121_CR34","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s40265-021-01631-w","volume":"81","author":"N Solish","year":"2021","unstructured":"Solish N, Carruthers J, Kaufman J, Rubio RG, Gross TM, Gallagher CJ (2021) Over-view of DaxibotulinumtoxinA for injection: a novel formulation of botulinum toxin type A. Drugs 81:2091\u20132101","journal-title":"Drugs"},{"issue":"10","key":"3121_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/toxins17100501","volume":"17","author":"U St\u00e5hl","year":"2025","unstructured":"St\u00e5hl U, Lekholm E, Hamnevik E, Fredriksson R, Shridharani SM, Taghetchian K, Cohen JL, Nestor MS, Liljegren Sundberg \u00c5 (2025) RelabotulinumtoxinA, a ready-to-use formulation neuromodulator manufactured with PEARL\u2122 technology to maintain high biological and specific activity. Toxins (Basel) 17(10):501. https:\/\/doi.org\/10.3390\/toxins17100501","journal-title":"Toxins (Basel)"},{"key":"3121_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.febslet.2011.12.037","volume":"586","author":"J Strotmeier","year":"2012","unstructured":"Strotmeier J, Willjes G, Binz T, Rummel A (2012) Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett 586:310\u2013313","journal-title":"FEBS Lett"},{"key":"3121_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.toxicon.2019.04.018","volume":"166","author":"D Wang","year":"2019","unstructured":"Wang D, Qu J, Jiang H, Jiang Y (2019) The safety and efficacy of botulinum toxin for management of scars: a systematic review with meta-analysis and trial sequential analysis. Toxicon 166:24\u201333","journal-title":"Toxicon"},{"key":"3121_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/PL00004951","volume":"355","author":"K Wohlfarth","year":"1997","unstructured":"Wohlfarth K, G\u00f6schel H, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 355:335\u2013340","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3121_CR39","doi-asserted-by":"publisher","first-page":"847e","DOI":"10.1097\/PRS.0000000000005029","volume":"142","author":"SG Yoelin","year":"2018","unstructured":"Yoelin SG, Dhawan SS, Vitarella D, Ahmad W, Hasan F, Abushakra S (2018) Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: results of a phase 2, randomized, placebo-controlled, ascending-dose study. Plast Reconstr Surg 142:847e\u2013855e. https:\/\/doi.org\/10.1097\/PRS.0000000000005029","journal-title":"Plast Reconstr Surg"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03121-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03121-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03121-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:00:16Z","timestamp":1783090816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03121-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3121"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03121-3","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}